Qatar – Pharmaceuticals & Healthcare Report Q3 2014

July 27, 2014 5:57 pm0 commentsViews: 187
Source : Google

Source : Google

Medicine prices are expected to decline shortly in Qatar amid the ‘imminent’ unification of medicine importation channels and the adoption of a new medicine pricing mechanism by the member countries of the Gulf Co-operation Council (GCC). The unified regional pharmaceutical pricing policy among GCC member states will reduce medicine prices in Qatar and improve its national drug accessibility, if implemented properly. Although the drug pricing controls can potentially negatively affect multinationals’ revenues in the country, increasing volume sales will at least partially offset the effect. As massive hydrocarbon wealth is spread generously across the country’s native population, Qatar’s pharmaceutical market will remain attractive to multinationals.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.63bn (USD449mn) in 2013 to QAR1.82bn (USD499mn) in 2014; +11.3% in local currency and 11.3% in US dollar terms. Forecast in line with Q 2 14 .
  • Healthcare: QAR16.75bn (USD4.60bn) in 2013 to QAR18.70bn (USD5.14bn) in 2014; +11.7% in both local currency and US dollar terms. Forecast revised upwards due to macroeconomic modifications.

Risk/Reward Rating: Qatar’s risks are particularly low in comparison with the rest of the MEA region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar’s high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases creates an environment in which there is strong potential for market growth. On account of shifts within BMI’s Pharmaceutical Risk/Reward Rating Index for the Middle East and Africa matrix, in Q314, Qatar has moved up again one position in the MEA matrix to reclaim fifth place with the country’s scores higher this quarter scoring 53.5 out of 100.

Key Trends And Developments

  • In May 2014, Qatar Airways Cargo’s India focus continues with the company launching a new weekly freighter service between the airline’s hubs in Doha…

The Qatar Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)’s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI’s Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatari pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI’s independent pharmaceutical and healthcare industry forecasts for Qatar to test other views – a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.


BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

[Source: fastmr]

Comment this Post

You must be logged in to post a comment.

Recent Comments